Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 145-159

  Schulert, Grant S ^a   Grom, Alexei A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

cytokine storm; hemophagocytic lymphohistiocytosis; hyperferritinemia; Still's disease; systemic juvenile idiopathic arthritis

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; BLOOD CLOTTING DISORDER; CYTOKINE STORM; CYTOPENIA; DISEASE ASSESSMENT; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERFERRITINEMIA; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LIVER DYSFUNCTION; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY;

ADRENAL CORTEX HORMONES; CYCLOSPORINE; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGE ACTIVATION SYNDROME; MOLECULAR TARGETED THERAPY;

EID: 84921412381     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-061813-012806     Document Type: Article

References (100)

1. HadchouelM, Prieur AM, Griscelli C. 1985. Acute hemorrhagic, hepatic, and neurologicmanifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J. Pediatr. 106:561-66
2. Mouy R, Stephan JL, Pillet P, et al. 1996. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J. Pediatr. 129:750-54
3. Grom AA, Passo M. 1996. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J. Pediatr. 129:630-32
4. Ravelli A, De Benedetti F, Viola S, MartiniA. 1996. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J. Pediatr. 128:275-78
5. Stephan JL, Kone-Paut I, Galambrun C, et al. 2001. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology 40:1285-92
6. Sawhney S, Woo P, Murray KJ. 2001. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch. Dis. Childhood 85:421-26
7. Favara BE, Feller AC, Pauli M, et al. 1997. Contemporary classification of histiocytic disorders. The WHOCommittee onHistiocytic/Reticulum Cell Proliferations. ReclassificationWorking Group of the Histiocyte Society. Med. Pediatr. Oncol. 29:157-66
8. Jordan MB, Allen CE, Weitzman S, et al. 2011. How I treat hemophagocytic lymphohistiocytosis. Blood 118:4041-52
9. ZhangKJ, Jordan MB, Marsh R, et al. 2011. Hypomorphic mutations in PRF1, MUNC13-4, andSTXBP2 are associated with adult-onset familial HLH. Blood 118:5794-98
10. Athreya BH. 2002. Is macrophage activation syndrome a new entity?. Clin. Exp. Rheumatol. 20:121-23
11. Ramanan AV, Schneider R. 2003. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 30:401-3
12. Parodi A, Davi S, Pringe AB, et al. 2009. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 60:3388-99
13. Avcin T, Tse SM, Schneider R, et al. 2006. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J. Pediatr. 148:683-86
14. Latino GA, Manlhiot C, Yeung RS, et al. 2010. Macrophage activation syndrome in the acute phase of Kawasaki disease. J. Pediatr. Hematol./Oncol. 32:527-31
15. Simonini G, Pagnini I, Innocenti L, et al. 2010. Macrophage activation syndrome/hemophagocytic lymphohistiocytosis and Kawasaki disease. Pediatr. Blood Cancer 55:592
16. Dhote R, Simon J, Papo T, et al. 2003. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 49:633-39
17. Lin CI, Yu HH, Lee JH, et al. 2012. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin. Rheumatol. 31:1223-30
18. Moradinejad MH, Ziaee V. 2011. The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr. 63:459-66
19. Bleesing J, Prada A, Siegel DM, et al. 2007. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 56:965-71
20. Behrens EM, Beukelman T, Paessler M, Cron RQ. 2007. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 34:1133-38
21. Henter JI, Horne A, Arico M, et al. 2007. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48:124-31
22. Ravelli A, Magni-Manzoni S, Pistorio A, et al. 2005. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr. 146:598-604
23. Davi S, Consolaro A, Guseinova D, et al. 2011. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J. Rheumatol. 38:764-68
24. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. 1999. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286:1957-59
25. Feldmann J, Callebaut I, Raposo G, et al. 2003. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115:461-73
26. zur Stadt U, Schmidt S, Diler AS, et al. 2005. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Genet. 14:827-34
27. Crozat K, HoebeK, Ugolini S, et al. 2007. Jinx, anMCMVsusceptibility phenotype caused by disruption of Unc13d: amousemodel of type 3 familial hemophagocytic lymphohistiocytosis. J. Exp.Med. 204:853-63
28. zur Stadt U, Rohr J, SeifertW, et al. 2009. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused bymutations in Munc18-2 and impaired binding to Syntaxin 11.Am. J. Hum. Genet. 85:482-92
29. Bode SF, Lehmberg K, Maul-Pavicic A, et al. 2012. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res. Ther. 14:213-25
30. Grom AA, Villanueva J, Lee S, et al. 2003. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142:292-96
31. KaufmanKM, Linghu B, Szustakowski JD, et al. 2014. Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheum. In press
32. Zhang K, Biroschak J, Glass DN, et al. 2008. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 58:2892-96
33. Vastert SJ, van Wijk R, D'Urbano LE, et al. 2010. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology 49:441-49
34. Jordan MB, Hildeman D, Kappler J, Marrack P. 2004. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104:735-43
35. Pachlopnik Schmid J, Ho CH, Chretien F, et al. 2009. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin-And Rab27a-deficient mice. EMBOMol.Med. 1:112-24
36. Pachlopnik Schmid J, Ho CH, Diana J, et al. 2008. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur. J. Immunol. 38:3219-25
37. Billiau AD, RoskamsT, Van Damme-Lombaerts R, et al. 2005. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6-And TNF-Alpha-producing macrophages. Blood 105:1648-51
38. Krebs P, Crozat K, Popkin D, et al. 2011. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood 117:6582-88
39. Pascual V, Allantaz F, Arce E, et al. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479-86
40. Fall N, Barnes M, Thornton S, et al. 2007. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 56:3793-804
41. Behrens EM, Canna SW, Slade K, et al. 2011. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J. Clin. Invest. 121:2264-77
42. Henter JI, Elinder G, Soder O, et al. 1991. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78:2918-22
43. Henter JI, Andersson B, Elinder G, et al. 1996. Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. Med. Pediatr. Oncol. 27:21-25
44. Sumegi J, Barnes MG, Nestheide SV, et al. 2011. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood 117:e151-60
45. Gattorno M, Piccini A, Lasiglie D, et al. 2008. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58:1505-15
46. Nigrovic PA, Mannion M, Prince FH, et al. 2011. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63:545-55
47. Zeft A, Hollister R, LaFleur B, et al. 2009. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskeletal Dis. 15:161-64
48. Fitzgerald AA, Leclercq SA, Yan A, et al. 2005. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52:1794-803
49. Quartier P, AllantazF, Cimaz R, et al. 2011.Amulticentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70:747-54
50. Ruperto N, Brunner HI, Quartier P, et al. 2012. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367:2396-406
51. Kelly A, Ramanan AV. 2008. A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol. 4:615-20
52. Miettunen PM, Narendran A, Jayanthan A, et al. 2011. Successful treatment of severe paediatric rheumatic disease-Associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 50:417-19
53. Durand M, Troyanov Y, Laflamme P, Gregoire G. 2010. Macrophage activation syndrome treated with anakinra. J. Rheumatol. 37:879-80
54. Grom AA, Brunner HI, Ruperto N, et al. 2014. Canakinumab in systemic juvenile idiopathic arthritis: impact on the rate and clinical presentation of macrophage activation syndrome. Ann. Rheum. Dis. 73(Suppl. 2):Abstr. FRI 0528
55. de Benedetti F, Massa M, Robbioni P, et al. 1991. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34:1158-63
56. Xu XJ, Tang YM, Song H, et al. 2012. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J. Pediatr. 160:984-90
57. Strippoli R, Carvello F, Scianaro R, et al. 2012. Amplification of the response to toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 64:1680-88
58. de Benedetti F, BrunnerHI, RupertoN, et al. 2012. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367:2385-95
59. Kobayashi M, Takahashi Y, Yamashita H, et al. 2011. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-Activation syndrome. Mod. Rheumatol./Jpn. Rheum. Assoc. 21:92-96
60. Shimizu M, Nakagishi Y, Kasai K, et al. 2012. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-Associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 58:287-94
61. Chiossone L, Audonnet S, Chetaille B, et al. 2012. Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front. Immunol. 3:239-49
62. van Dommelen SL, Sumaria N, Schreiber RD, et al. 2006. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity 25:835-48
63. Makay B, Yilmaz S, Turkyilmaz Z, et al. 2008. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr. Blood Cancer 50:419-21
64. Prahalad S, Bove KE, Dickens D, et al. 2001. Etanercept in the treatment of macrophage activation syndrome. J. Rheumatol. 28:2120-24
65. Aeberli D, Oertle S, Mauron H, et al. 2002. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med. Wkly. 132:414-22
66. Stern A, Riley R, Buckley L. 2001. Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskeletal Dis. 7:252-56
67. Puren AJ, Fantuzzi G, Dinarello CA. 1999. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1 beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc. Natl. Acad. Sci. USA 96:2256-61
68. Dinarello CA. 2007. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 27:98-114
69. Mazodier K, Marin V, Novick D, et al. 2005. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106:3483-89
70. Maeno N, Takei S, Imanaka H, et al. 2004. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-Activation syndrome. Arthritis Rheum. 50:1935-38
71. Kawashima M, Yamamura M, Taniai M, et al. 2001. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. 44:550-60
72. Novick D, SchwartsburdB, PinkusR, et al. 2001.Anovel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14:334-42
73. Novick D, Elbirt D, Miller G, et al. 2009. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. Cytokine 48:103-4
74. Favilli F, Anzilotti C, Martinelli L, et al. 2009. IL-18 activity in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1173:301-9
75. Shimizu M, Yokoyama T, Yamada K, et al. 2010. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-Associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 49:1645-53
76. de JagerW, Vastert SJ, Beekman JM, et al. 2009. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60:2782-93
77. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukocyte Biol. 75:163-89
78. Mosser DM. 2003. The many faces of macrophage activation. J. Leukocyte Biol. 73:209-12
79. Mantovani A, Sica A, Sozzani S, et al. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25:677-86
80. Zoller EE, Lykens JE, Terrell CE, et al. 2011. Hemophagocytosis causes a consumptive anemia of inflammation. J. Exp. Med. 208:1203-14
81. Martinez FO, Sica A, Mantovani A, Locati M. 2008. Macrophage activation and polarization. Front. Biosci. 13:453-61
82. Sikora KA, Fall N, Thornton S, Grom AA. 2012. The limited role of interferon-gamma in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness. Arthritis Rheum. 64:3799-808
83. Ogilvie EM, Khan A, Hubank M, et al. 2007. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 56:1954-65
84. Bracaglia C, Caiello I, de Graaf K, et al. 2014. Interferon-gamma in macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: high levels in patients and a role in a murine MAS model. Presented at Eur. Paediatr. Rheumatol. Congr., 21st, Belgrade (Abstr.)
85. Osugi Y, Hara J, Tagawa S, et al. 1997. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89:4100-3
86. Takada H, Takahata Y, Nomura A, et al. 2003. Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin. Exp. Immunol. 133:448-53
87. de Saint Basile G, Menasche G, Latour S. 2011. Inherited defects causing hemophagocytic lymphohistiocytic syndrome. Ann. N. Y. Acad. Sci. 1246:64-76
88. Ravelli A, Grom AA, Behrens EM, Cron RQ. 2012. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immunity 13:289-98
89. Ibarra MF, Klein-Gitelman M, Morgan E, et al. 2011. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin. Vaccine Immunol. 18:609-14
90. Quesnel B, Catteau B, Aznar V, et al. 1997. Successful treatment of juvenile rheumatoid arthritis associated haemophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF. Br. J. Haematol. 97:508-10
91. Gupta AA, Tyrrell P, Valani R, et al. 2009. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. J. Pediatr. Hematol./Oncol. 13 81-84
92. Sung L, King SM, Carcao M, et al. 2002. Adverse outcomes in primary hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol./Oncol. 24:550-54
93. Coca A, Bundy KW, Marston B, et al. 2009. Macrophage activation syndrome: serological markers and treatment with anti-Thymocyte globulin. Clin. Immunol. 132:10-18
94. Mahlaoui N, Ouachee-ChardinM, de Saint Basile G, et al. 2007. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 120:e622-28
95. Su IJ, Wang CH, Cheng AL, Chen RL. 1995. Hemophagocytic syndrome in Epstein-Barr virusassociated T-lymphoproliferative disorders: disease spectrum, pathogenesis, andmanagement. Leukemia Lymphoma 19:401-6
96. Larroche C, Mouthon L, Casadevall N, et al. 2000. Successful treatment of thymoma-Associated pure red cell aplasia with intravenous immunoglobulins. Eur. J. Haematol. 65:74-76
97. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. 2007. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-Associated hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol./Oncol. 29:569-73
98. Bosman G, Langemeijer SM, Hebeda KM, et al. 2009. The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis. Netherlands J. Med. 67:364-65
99. Marsh RA, Allen CE, McClain KL, et al. 2013. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr. Blood Cancer 60:101-9
100. Keith MP, Pitchford C, Bernstein WB. 2012. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus. J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskeletal Dis. 18:134-37